Stojanović-Rundić, Suzana (23037160700)Suzana (23037160700)Stojanović-RundićPlešinac-Karapandžić, Vesna (23474669800)Vesna (23474669800)Plešinac-KarapandžićDedović-Stojaković, Jelena (57914960000)Jelena (57914960000)Dedović-StojakovićMijalković, Nenad (57211792937)Nenad (57211792937)MijalkovićŠkrelja, Violeta (57248313100)Violeta (57248313100)ŠkreljaMiletić, Nebojša (6507207374)Nebojša (6507207374)MiletićĐurić-Stefanović, Aleksandra (16021199600)Aleksandra (16021199600)Đurić-Stefanović2025-06-122025-06-122021https://doi.org/10.2298/SARH200322025Shttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85114366653&doi=10.2298%2fSARH200322025S&partnerID=40&md5=47f8b3eff0971ad57ccded58758e58dchttps://remedy.med.bg.ac.rs/handle/123456789/4075Introduction Colorectal cancer is the third most common cancer and one of the leading causes of cancer-related deaths in men and women worldwide. The contemporary multidisciplinary approach has decreased rates of local recurrence and improved outcomes in metastatic colorectal cancer. We present a case of a primarily metastatic rectal cancer patient who underwent multidisciplinary planned treatment and showed complete response with now three years disease-free survival. Case outline A 61-year-old female was diagnosed with a T4N2M1a rectal adenocarcinoma at the age of 58. She underwent six cycles of systemic chemotherapy capecitabine-oxaliplatin plus bevacizumab with partial response confirmed by diagnostic imaging procedures. According to multidisciplinary board decision, preoperative radiotherapy treatment was administered with concomitant capecitabinebased chemotherapy. A 50.4 Gy total dose was delivered with 1.8 Gy fraction dose. After concomitant chemoradiotherapy treatment, two more cycles of systemic chemotherapy capecitabine-oxaliplatin plus bevacizumab were administered. One month after completion of systemic chemotherapy, primary rectal cancer was operated with a complete response on histopathologic specimens. Six weeks following previous surgery, metastasectomy of lung deposits was performed; histopathology confirmed metastatic adenocarcinoma of colorectal origin. Three more cycles of postoperative chemotherapy capecitabine-oxaliplatin plus bevacizumab were administered. Conclusion On regular follow-up, no evidence of disease was shown, with disease-free survival of three years. The treatment improved the patient’s quality of life. © 2021, Serbia Medical Society. All rights reserved.ChemotherapyRadiotherapyRectal cancerStage IVSurgical treatment